The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma

Prostate cancer is the most commonly diagnosed malignancy and second leading cause of cancer death among men in the United States. In recent years, several new agents, including cancer immunotherapies, have been approved or are currently being investigated in late-stage clinical trials for the manag...

Szczegółowa specyfikacja

Zapisane w:
Opis bibliograficzny
Wydane w:J Immunother Cancer
Główni autorzy: McNeel, Douglas G., Bander, Neil H., Beer, Tomasz M., Drake, Charles G., Fong, Lawrence, Harrelson, Stacey, Kantoff, Philip W., Madan, Ravi A., Oh, William K., Peace, David J., Petrylak, Daniel P., Porterfield, Hank, Sartor, Oliver, Shore, Neal D., Slovin, Susan F., Stein, Mark N., Vieweg, Johannes, Gulley, James L.
Format: Artigo
Język:Inglês
Wydane: BioMed Central 2016
Hasła przedmiotowe:
Position Article and Guidelines
Dostęp online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5170901/
https://ncbi.nlm.nih.gov/pubmed/28031820
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-016-0198-x
Etykiety: Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!

Podobne zapisy